Ryan Scott | Authors


Acute GVHD Responds Quickly to Itolizumab Treatment in Phase 1b Trial

May 03, 2022

The positive results from EQUTE informed the doses that will be evaluated in the phase 3 EQUATOR trial of tolizumab versus placebo in combination with corticosteroids as a first-line treatment in patients with acute graft-versus-host disease.

Understanding irAEs Is Vital for IO Combo Use in HCC

October 05, 2021

In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.